| ²é¿´: 1912 | »Ø¸´: 2 | |||
| ±¾Ìû²úÉú 1 ¸ö ²©Ñ§EPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
yanzhang722ľ³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖú¶÷Ìæ¿¨Î¤ÔÁÏÒ©Àí»¯ÐÔÖÊ
|
||
| È۵㡢±ÈÐý¹â¶È¡¢ÈܽâÐÔ¡¢pka£¬½âÀë³£ÊýµÈ |
» ²ÂÄãϲ»¶
311£¨085601£©Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
305Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸±±»¯085600²ÄÁÏר˶275|ÓÐÎÄÕÂרÀû£üÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸»ªÀí£¬ÊýÒ»Ó¢Ò»285ÇóAÇøµ÷¼Á
ÒѾÓÐ12È˻ظ´
289Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
ʳƷ¹¤³Ìר˶һ־ԸÖк£Ñó309Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
ÉúÎïѧѧ˶£¬Ò»Ö¾Ô¸ºþÄÏ´óѧ£¬³õÊԳɼ¨338
ÒѾÓÐ6È˻ظ´
321Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
343Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
±¾¿ÆÐÂÄÜÔ´¿ÆÑ§Ó빤³Ì£¬Ò»Ö¾Ô¸»ªÀíÄܶ¯285Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÇóÖú¶÷Ìæ¿¨Î¤ÔÁÏÒ©Àí»¯ÐÔÖÊ
ÒѾÓÐ8È˻ظ´
:)´ó¼ÒºÃ£¬ÎÒÊÇÐÂÊÖ£¬ÎÒÏëÇë½Ìϸ÷λÈçºÎ²éѯһÖÖ»¯Ñ§ÔÁÏÒ©µÄÀí»¯ÐÔÖÊ£¿
ÒѾÓÐ9È˻ظ´
ÇóÖú¹ØÓÚ»¯ºÏÎïÀí»¯ÐÔÖʲéѯµÄÍøÕ¾ºÍÊý¾Ý¿â
ÒѾÓÐ9È˻ظ´
¡¾Ô´´¡¿×ªÈö÷Ìæ¿¨Î¤¡¢ÄªÎ÷ɳÐÇ¡¢ÒÁÂíÌæÄáµÈ¶àÖÖÔÁÏÒ©¹¤ÒÕ£¨º¬¸÷ÖÖ±ê×¼£©£¬·Ç³ÏÎðÈÅ
ÒѾÓÐ6È˻ظ´
¡¾ÇóÖú¡¿¦Á-Ï㸽ͪµÄÀí»¯ÐÔÖʵȷ½ÃæµÄÑо¿
ÒѾÓÐ4È˻ظ´
¡¾ÇóÖú¡¿¹ØÓÚÉú²úµÄÔÁÏÒ©µÄȱ·¦ÎÊÌâ
ÒѾÓÐ7È˻ظ´
¡¾ÇóÖú¡¿ÔõÃ´ÍÆ¶ÏÓлúÎïµÄÀí»¯ÐÔÖÊ
ÒѾÓÐ11È˻ظ´
¡¾ÇóÖú¡¿ÇëÎÊ180#ÈܼÁÓÍÀí»¯ÐÔÖÊ£¿
ÒѾÓÐ4È˻ظ´
zb19821212
Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)
ÍÚ¾òîѰ׷Û....
- ²©Ñ§EPI: 347
- Ó¦Öú: 148 (¸ßÖÐÉú)
- ½ð±Ò: 7319.8
- É¢½ð: 250
- ºì»¨: 10
- Ìû×Ó: 4606
- ÔÚÏß: 335.1Сʱ
- ³æºÅ: 533729
- ×¢²á: 2008-03-26
- ÐÔ±ð: GG
- רҵ: »¯Ñ§·´Ó¦¹¤³Ì
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
yanzhang722(½ð±Ò+10): ¡ïÓаïÖú 2012-02-24 08:41:54
|
https://www.aoxchem.com/chanpinyingyong/220.htmlÀïÃæÓÐÐý¹â¶ÈÊý¾Ý https://www.fincchem.cn/a7.htmÀïÃæÓÐÈÛµãÊý¾Ý |
2Â¥2012-02-21 12:27:18
³ÕÒÄ×ÓÆ¤
°æÖ÷ (ÎÄ̳¾«Ó¢)
ÀÏÆ¦
- ²©Ñ§EPI: 105
- Ó¦Öú: 2016 (½²Ê¦)
- ¹ó±ö: 5.368
- ½ð±Ò: 54487.3
- É¢½ð: 41688
- ºì»¨: 303
- ɳ·¢: 1206
- Ìû×Ó: 32611
- ÔÚÏß: 4303.7Сʱ
- ³æºÅ: 674536
- ×¢²á: 2008-12-14
- ÐÔ±ð: GG
- רҵ: ÎÞÉñÂÛ
- ¹ÜϽ: ÈËÎÄÉç¿Æ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
yanzhang722(½ð±Ò+10, ²©Ñ§EPI+1): ¡ïÓаïÖú 2012-02-24 08:41:35
|
Title: Entecavir CAS Registry Number: 142217-69-4 CAS Name: 2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one Molecular Formula: C12H15N5O3 Molecular Weight: 277.28 Percent Composition: C 51.98%, H 5.45%, N 25.26%, O 17.31% Literature References: Deoxyguanine nucleoside analog; inhibits hepatitis B virus (HBV) DNA polymerase. Prepn: R. Zahler, W. A. Slusarchyk, EP 481754; eidem, US 5206244 (1992, 1993 both to Squibb); G. S. Bisacchi et al., Bioorg. Med. Chem. Lett. 7, 127 (1997). In vitro antiviral activity: S. F. Innaimo et al, Antimicrob. Agents Chemother. 41, 1444 (1997). Review of pharmacology and clinical experience: P. Honkoop, R. A. de Man, Expert Opin. Invest. Drugs 12, 683-688 (2003); T. Shaw, S. Locarnini, Expert Rev. Anti Infect. Ther. 2, 853-871 (2004). Clinical comparisons with lamivudine in chronic hepatitis B: T.-T. Chang et al., N. Engl. J. Med. 354, 1001 (2006); C.-L. Lai et al., ibid. 1011. Derivative Type: Monohydrate CAS Registry Number: 209216-23-9 Manufacturers' Codes: BMS-200475; SQ-200475 Trademarks: Baraclude (BMS) Molecular Formula: C12H15N5O3.H2O Molecular Weight: 295.29 Percent Composition: C 48.81%, H 5.80%, N 23.72%, O 21.67% Properties: White to off-white powder, mp >220¡ã. [a]D +35.0¡ã (c = 0.38 in water). Soly in water: 2.4 mg/ml. pH of saturated soln in water is 7.9 at 25¡ã¡À0.5¡ã. Melting point: mp >220¡ã Optical Rotation: [a]D +35.0¡ã (c = 0.38 in water) Therap-Cat: Antiviral. Keywords: Antiviral; Purines/Pyrimidinones. |

3Â¥2012-02-21 13:19:43














»Ø¸´´ËÂ¥